X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ELDER PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ELDER PHARMA GSK PHARMA/
ELDER PHARMA
 
P/E (TTM) x 60.4 -0.2 - View Chart
P/BV x 11.3 0.1 11,180.6% View Chart
Dividend Yield % 2.6 0.0 -  

Financials

 GSK PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
ELDER PHARMA
Jun-14
GSK PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760380 726.3%   
Low Rs2,040188 1,085.1%   
Sales per share (Unadj.) Rs339.0491.2 69.0%  
Earnings per share (Unadj.) Rs41.4-3.2 -1,301.8%  
Cash flow per share (Unadj.) Rs45.914.4 318.6%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.9376.5 64.5%  
Shares outstanding (eoy) m84.7020.54 412.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.10.6 1,224.4%   
Avg P/E ratio x57.9-89.3 -64.9%  
P/CF ratio (eoy) x52.319.7 265.3%  
Price / Book Value ratio x9.90.8 1,309.9%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,2805,833 3,484.8%   
No. of employees `000NANA-   
Total wages/salary Rs m5,2342,179 240.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m28,71510,089 284.6%  
Other income Rs m545257 212.6%   
Total revenues Rs m29,26010,346 282.8%   
Gross profit Rs m5,059-792 -638.8%  
Depreciation Rs m380361 105.2%   
Interest Rs m22,756 0.1%   
Profit before tax Rs m5,222-3,653 -143.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1783,713 4.8%   
Tax Rs m1,892125 1,511.8%   
Profit after tax Rs m3,508-65 -5,368.0%  
Gross profit margin %17.6-7.8 -224.4%  
Effective tax rate %36.2-3.4 -1,057.5%   
Net profit margin %12.2-0.6 -1,886.1%  
BALANCE SHEET DATA
Current assets Rs m21,8159,240 236.1%   
Current liabilities Rs m15,9999,998 160.0%   
Net working cap to sales %20.3-7.5 -269.7%  
Current ratio x1.40.9 147.5%  
Inventory Days Days6446 137.3%  
Debtors Days Days1960 31.2%  
Net fixed assets Rs m12,47510,124 123.2%   
Share capital Rs m847206 411.8%   
"Free" reserves Rs m19,7265,582 353.4%   
Net worth Rs m20,5737,734 266.0%   
Long term debt Rs m64,889 0.1%   
Total assets Rs m39,47522,882 172.5%  
Interest coverage x2,612.0-0.3 -802,973.0%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.70.4 165.0%   
Return on assets %8.911.8 75.6%  
Return on equity %17.1-0.8 -2,017.8%  
Return on capital %26.222.3 117.7%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m564307 184.0%   
Fx outflow Rs m7,429125 5,929.0%   
Net fx Rs m-6,865181 -3,786.5%   
CASH FLOW
From Operations Rs m4,72811,754 40.2%  
From Investments Rs m-1,042-561 185.9%  
From Financial Activity Rs m-3,066-6,762 45.3%  
Net Cashflow Rs m6204,432 14.0%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 16.8 141.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 36.1 42.7%  
Shareholders   102,036 16,479 619.2%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 11, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS